Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Prevention and risk

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Interventions that have even quite modest effects at the individual level could drastically reduce the future burden of dementia associated with Alzheimer's disease at the population level. In the past three decades, both pharmacological and lifestyle interventions have been studied for the prevention of cognitive decline or dementia in randomised controlled trials of individuals mostly aged older than 50-55 years with or without risk factors for Alzheimer's disease. Several trials testing the effects of physical activity, cognitive training, or antihypertensive interventions showed some evidence of efficacy on a primary cognitive endpoint. However, most of these trials had short follow-up periods, and further evidence is needed to confirm effectiveness and establish the optimum design or dose of interventions and ideal target populations. Important innovations in ongoing trials include the development of multidomain interventions, and the use of biomarker or genetic inclusion criteria. Challenges include the use of adaptive trial designs, the development of standardised, sensitive outcome measures, and the need for interventions that can be implemented in resource-poor settings.

What this study adds

Evidence grade: High

This is a narrative review. This review states that some trials of physical activity, cognitive training, or antihypertensive interventions showed some evidence of efficacy on cognitive endpoints, but most had short follow-up and further evidence is needed. It discusses ongoing multidomain interventions and the need for standardized outcome measures.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Andrieu, S., Coley, N., Lovestone, S., Aisen, P. S., & Vellas, B. (2015). Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(15)00153-2

Vancouver

Andrieu S, Coley N, Lovestone S, Aisen PS, Vellas B. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. The Lancet. Neurology. 2015. doi:10.1016/s1474-4422(15)00153-2. PMID: 26213339.

BibTeX

@article{andrieu2015-26213339,
  author  = {Andrieu, S. and Coley, N. and Lovestone, S. and Aisen, P. S. and Vellas, B.},
  title   = {{Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions}},
  journal = {The Lancet. Neurology},
  year    = {2015},
  doi     = {10.1016/s1474-4422(15)00153-2},
  pmid    = {26213339},
  url     = {https://doi.org/10.1016/s1474-4422(15)00153-2}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review states that some trials of physical activity, cognitive training, or antihypertensive interventions showed some evidence of efficacy on cognitive endpoints, but most had short follow-up and further evidence is needed. It discusses ongoing multidomain interventions and the need for standardized outcome measures.

Study details

How this study scored 58/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 4 of 5; Impact for its field and year 5 of 6; Cited by studies here 3 of 6; Still being cited 3 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 58 of 100.58 of 100 points earned42 not earned

Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (The Lancet. Neurology)
Journal's citation record 3 / 4 The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2015 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 292 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 22.5 citations a year over 13 year(s) since 2015
Impact for its field and year 5 / 6 Cited 25.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 24 other studies in this library
Still being cited 3 / 4 Cited 52 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Bruno J. Vellas: h-index 135 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Oxford: institution h-index 2,205 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 26213339)
Free to read 0 / 2 Behind a paywall — scores zero
Total 58 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 49.

Later studies that cite this one

24 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Prevention and risk from nearby years

Also in Prevention and risk

265 studies in the library are filed under Prevention and risk with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Prevention and risk hub.

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →